| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/30/1999 | WO1999037325A3 Method for treating acute intermittent porphyria (aip) and other porphyric diseases |
| 09/30/1999 | WO1999037167A3 Process of improving the stability of vitamin d in a nutritional product containing hydrolyzed protein and product produced thereby |
| 09/30/1999 | WO1999036562A9 Nucleotide expression systems with reduced immunogenicity for use in gene therapy |
| 09/30/1999 | WO1999035277A3 Recombinant, active caspases and uses thereof |
| 09/30/1999 | WO1999035266A3 Human urotensin ii |
| 09/30/1999 | WO1999035246A9 Novel steroid-activated nuclear receptors and uses therefor |
| 09/30/1999 | WO1999033853A3 Carbohydrates, useful in solid delivery systems |
| 09/30/1999 | WO1999032149A9 GENES FOR MALE ACCESSORY GLAND PROTEINS IN $i(DROSOPHILA MELANOGASTER) |
| 09/30/1999 | WO1999031122A9 Antipicornaviral compounds and methods for their use and preparation |
| 09/30/1999 | WO1999027897A9 Site-specific preparation of polyethylene glycol-grf conjugates |
| 09/30/1999 | WO1999014327A3 Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer |
| 09/30/1999 | WO1999013898A9 EC-3, AN INHIBITOR OF α4β1 AND α4β7 INTEGRINS |
| 09/30/1999 | WO1999011791A3 Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| 09/30/1999 | WO1998018824A9 Human tumor necrosis factor receptor-like 2 |
| 09/30/1999 | DE19813774A1 Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF) Parapoxvirus-coded vascular endothelial growth factor (VEGF PPV) |
| 09/30/1999 | DE19813137A1 New camptothecin glyco-conjugate compounds |
| 09/30/1999 | DE19812195A1 Stoffzusammensetzung zur Gewebebildung Composition for tissue formation |
| 09/30/1999 | CA2326053A1 Use of scatter factor to enhance angiogenesis |
| 09/30/1999 | CA2325585A1 Inflammatory mediator antagonists |
| 09/30/1999 | CA2324648A1 Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
| 09/30/1999 | CA2324616A1 Trimeric antigenic o-linked glycopeptide conjugates, methods of preparation and uses thereof |
| 09/30/1999 | CA2324568A1 Sustained-release preparation of physiologically active polypeptide and production thereof |
| 09/30/1999 | CA2324566A1 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
| 09/30/1999 | CA2324494A1 Apo-2 ligand-anti-her-2 antibody synergism |
| 09/30/1999 | CA2324350A1 Cardiac-derived stem cells |
| 09/30/1999 | CA2324345A1 Human vault rna |
| 09/30/1999 | CA2324340A1 Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses |
| 09/30/1999 | CA2323782A1 Methods for prevention and treatment of cancer |
| 09/30/1999 | CA2323760A1 Human casb12 polypeptide, a serine protease |
| 09/30/1999 | CA2323640A1 Human calcium-binding proteins |
| 09/30/1999 | CA2323605A1 Protein phosphatase-related molecules |
| 09/30/1999 | CA2323601A1 Casb414: antigen overexpressed in several tumors |
| 09/30/1999 | CA2323573A1 Medicament for preventing or treating papilloma virus-specific tumors |
| 09/30/1999 | CA2323526A1 Formulation having a papilloma virus-specific protein, and the production and use thereof |
| 09/30/1999 | CA2323501A1 Compounds related to pap-1 |
| 09/30/1999 | CA2323063A1 Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease |
| 09/30/1999 | CA2322779A1 Glycosyl sulfotransferase-3 |
| 09/30/1999 | CA2322773A1 Antisense modulation of human mdm2 expression |
| 09/30/1999 | CA2291066A1 Local delivery of long lasting therapeutic agents |
| 09/30/1999 | CA2290653A1 Streptococcus sag-a, a structural protein associated with sls activity |
| 09/30/1999 | CA2264951A1 Amino acid derivatives |
| 09/30/1999 | CA2233748A1 Medicine |
| 09/30/1999 | CA2233725A1 Hemoglobin-hydroxyethyl starch complexes |
| 09/29/1999 | EP0945512A2 Novel serine proteases |
| 09/29/1999 | EP0945506A1 Novel peptide, novel dna, and novel antibody |
| 09/29/1999 | EP0945505A1 Novel semaphorin gene: semaphorin w |
| 09/29/1999 | EP0945464A1 Specific binding members for human transforming growth factor beta; materials and methods |
| 09/29/1999 | EP0945463A2 Process for the preparation of human leukocyte (alpha) interferon |
| 09/29/1999 | EP0945461A1 Lipopeptides inducing T-cyxtotoxic lymphocytes and their use as vaccines |
| 09/29/1999 | EP0945136A1 Pharmaceutical preparation comprising ciclosporin |
| 09/29/1999 | EP0944725A1 Phosphodiesterase 8a |
| 09/29/1999 | EP0944724A1 USE OF A VECTOR EXPRESSING DNA POLYMERASE $g(b) AS MEDICINE |
| 09/29/1999 | EP0944723A2 Mammalian chemokines |
| 09/29/1999 | EP0944722A2 Pituitary-tumor-transforming-genes, and related products |
| 09/29/1999 | EP0944721A1 Adipocyte-specific differentiation-related protein |
| 09/29/1999 | EP0944719A1 Tryparedoxin peroxidase |
| 09/29/1999 | EP0944718A2 Tryparedoxin, expression plasmid, process of production, use, test system and pharmaceutical preparation |
| 09/29/1999 | EP0944651A2 Genes amplified in cancer cells |
| 09/29/1999 | EP0944650A1 Antithrombotic peptides derived from fibronectin type ii repeats |
| 09/29/1999 | EP0944649A1 METHYLATED, SmD HOMOLOGOUS PEPTIDES, REACTIVE WITH THE ANTIBODIES FROM SERA OF LIVING BEINGS AFFECTED WITH SYSTEMIC LUPUS ERYTHEMATOSUS |
| 09/29/1999 | EP0944648A1 Glp-1 derivatives |
| 09/29/1999 | EP0944647A1 Submucosa extracts |
| 09/29/1999 | EP0944646A1 Secreted proteins and polynucleotides encoding them |
| 09/29/1999 | EP0944645A1 INHIBITORS OF INTERLEUKIN-1beta CONVERTING ENZYME |
| 09/29/1999 | EP0944639A1 Synthetic glycoamines, methods for their use that affect cell |
| 09/29/1999 | EP0944597A1 Metalloproteinase inhibitors |
| 09/29/1999 | EP0944396A1 Compositions and methods for enhancing intestinal function |
| 09/29/1999 | EP0944395A1 Local use of il-1ra in corneal transplant rejection or disorders of the eye |
| 09/29/1999 | EP0944394A1 Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity |
| 09/29/1999 | EP0944393A1 Use of peptides for improving the incorporation of skin grafts |
| 09/29/1999 | EP0944382A1 Methods and compounds for treatment of abnormal uterine bleeding |
| 09/29/1999 | EP0880359A4 Nima interacting proteins |
| 09/29/1999 | EP0833842B1 Novel peptides for use in treatment of t-cell mediated cartilage destruction in autoimmune diseases |
| 09/29/1999 | EP0797447A4 Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| 09/29/1999 | EP0591281B1 Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them |
| 09/29/1999 | EP0474645B1 Protein complex |
| 09/29/1999 | CN1230223A High-affinity interleukin-4 muteins |
| 09/29/1999 | CN1230222A PTX-sensitive G proteins, prodn. and use thereof |
| 09/29/1999 | CN1230220A Therapy for 'alpha'-galactosidase deficiency |
| 09/29/1999 | CN1230198A Therapeutic multispecific compounds comprised of anti-FC'alpha' receptor antibodies |
| 09/29/1999 | CN1230196A Modified aminoacids, pharmaceuticals containing these compounds and method for their prodn. |
| 09/29/1999 | CN1230195A Treatment of immune disorders |
| 09/29/1999 | CN1230121A Means for treating prostate hypertrophy and prostate cancer |
| 09/29/1999 | CN1230120A Compounds that inhibit interaction between signal-transducing proteins and GLGF(PDZ/DHR) domain and uses thereof |
| 09/29/1999 | CN1230110A Cell adhesion inhibitors |
| 09/29/1999 | CN1230108A Temp. sensitive gel for sustained delivery of protein drugs |
| 09/29/1999 | CN1229677A Composition and methods using nitroxides to avoid oxygen toxicity |
| 09/29/1999 | CN1229676A Human growth hormone-containing aqueous pharmaceutical composition |
| 09/28/1999 | US5959177 Transgenic plants expressing assembled secretory antibodies |
| 09/28/1999 | US5959171 Method for the production of biologically active polypeptides in a mammal's |
| 09/28/1999 | US5959123 Reacating substituted amino acid with 3-amino-4-substituted-azetidine-2-one compound to form 3, 4-disubstituted-azetidine-2-one compound; useful for treating muscular dystrophy, arthritis, viral and parasitic infections |
| 09/28/1999 | US5959097 Oligonucleotide of 8 to 30 nucleotides which suppresses expression of signal transduction kinase; for treatment of infections; antiinflammatory/antitumor agents |
| 09/28/1999 | US5959096 For anticarcinogenic/antitumor/antiproliferative agents; antiinflammatory agents; treatment of psoriasis, and glioblastoma, bladder, breast, lung and tumor cancer |
| 09/28/1999 | US5959094 The present invention relates to a promoter sequence for the p75 tumor necrosis factor receptor (tnf-r), to its preparation and use. |
| 09/28/1999 | US5959087 The ligand is preferably an antibody, f(ab) fragment, single domain antibody (dabs) single chain antibody or a serum binding protein. |
| 09/28/1999 | US5959085 Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| 09/28/1999 | US5959084 Bispecific antibodies, methods of production and uses thereof |
| 09/28/1999 | US5959083 Tetravalent bispecific receptors, the preparation and use thereof |
| 09/28/1999 | US5959079 CREBA isoform |
| 09/28/1999 | US5959078 Amino acid sequence for enzyme involved in stimulation of neurite outgrowth and important to neural cell adhesion molecule binding; anticarcinogenic/antitumor/antimetastasis agents; antisense agents; diagnosis |